Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders

摘要

This commentary seeks to share some key insights relevant to optimizing COVID‐19 candidate therapeutics that were learned from attempts to optimize anti‐infective posology in settings where quality and timely availability of data is challenging, with particular focus on influenza, including experiences from H5N1 and pH1N1 outbreaks.